bis(1,3,4-thiadiazol-2-yl)disulfide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: bis(1,3,4-thiadiazol-2-yl)disulfide
• 英文别名: Bis(1,3,4-thiadiazol-2-yl) disulfide；2-(1,3,4-thiadiazol-2-yldisulfanyl)-1,3,4-thiadiazole
• 化学式: C₄H₂N₄S₄
• 分子量: 234.351
• InChiKey: SMNIKQNJCKSDIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  159
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-巯基-1,3,4-噻二唑 在 双氧水 作用下， 以 甲醇 为溶剂， 以85%的产率得到bis(1,3,4-thiadiazol-2-yl)disulfide
  参考文献：
  名称：

  Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes

  摘要：

  Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125-S124-S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112500

文献信息

• 10.1021/acs.jafc.4c04404
  作者：Zhang, Zhao-Sheng、He, Zhe、Shi, Yu、Guan, Mingming、Zhao, Dong-Sheng、Zhu, Di、Xiong, Lan-Tu、Li, Yasheng、Deng, Xin、Cui, Zi-Ning

  DOI：10.1021/acs.jafc.4c04404

  日期：——

  cause of food spoilage. Pseudomonas aeruginosa is a common foodborne pathogen that causes food spoilage and poses a serious threat to food safety. As a crucial target in antitoxicity strategies, the quorum sensing (QS) system shows promising potential for further development. The garlic extract diallyl disulfide exhibits inhibitory activity against the QS system of P. aeruginosa, with disulfide bonds

  微生物是食物腐败的最常见原因。铜绿假单胞菌是一种常见的食源性致病菌，可导致食品腐败变质，对食品安全构成严重威胁。作为抗毒性策略的关键目标，群体感应（QS）系统显示出进一步发展的广阔潜力。大蒜提取物二烯丙基二硫醚对铜绿假单胞菌QS系统具有抑制活性，其活性成分为二硫键。然而，其他对称二硫化物的生物活性尚未在这方面进行研究。该研究合成了 39 种含有二硫键的类似物，并评估了它们作为群体感应抑制剂 (QSI) 的活性。结果表明，对羟基苯基取代可以取代烯丙基，同时保持较强的生物活性。化合物2i减少了毒力因子的产生，观察到对弹性蛋白酶产生的最强抑制作用。在环丙沙星和妥布霉素等抗生素存在下观察到协同抑制作用。 2i成功抑制大蜡螟幼虫模型中的铜绿假单胞菌感染。使用转录组、表面等离子共振和分子对接的主要机制研究表明， 2i通过靶向 LasR 蛋白来抑制 QS 系统。因此，化合物2i可用于开发用于控制铜绿假单胞菌感染的
• Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes
  作者：Yi-xiang Xu、Yun-yuan Huang、Rong-rong Song、Yan-liang Ren、Xin Chen、Chao Zhang、Fei Mao、Xiao-kang Li、Jin Zhu、Shuai-shuai Ni、Jian Wan、Jian Li

  DOI：10.1016/j.ejmech.2020.112500

  日期：2020.10

  Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125-S124-S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.